CRANFORD, N.J., March 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will participate at the 31st Annual ROTH Conference. The conference will be held on March 17-19, 2019 at The Ritz Carlton, Laguna Niguel in Orange County, California.
During the conference, Executive Chairman, Mr. Leonard Mazur along with other members of management are scheduled to present in one-on-one meetings with investors and analysts. Management will discuss their critical care products; Mino-Lok® which is in Phase 3 trials and is enrolling patients, CITI-002, which is being prepared for a Phase 2b trial, and CITI-101 that is in pre-clinical stage. To arrange a meeting with management, please contact Mr. Andrew Scott: ascott@citiuspharma.com.
Citius Pharmaceuticals Management will present via pre-recoded webinar, available at this link http://wsw.com/webcast/roth33/ctxr/.
The webinar will also be available on the Company's website under the Investors section.
About the 31st Annual ROTH Conference
31st Annual ROTH Conference scheduled for March 17-19, 2019 at The Ritz Carlton, Laguna Niguel in Orange County, CA. Following the success of the previous year's events, the ROTH Conference, with close to 550 participating companies and over 4,700 attendees, will feature presentations from public and private companies in a variety of sectors including:
This gathering of institutional investors, private equity investors, VCs and executives, and service providers has become a must-attend event for anyone working in the small and mid-cap space.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
Contact:
Andrew Scott
Vice President, Corporate Development
(o) 908-967-6677
ascott@citiuspharma.com
SOURCE Citius Pharmaceuticals, Inc.
